At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-marketing Carcinogenicity Study of Bupropion
In Brief
An observational study evaluating Regular bupropion use, Regular SSRI (Selective serotonin reuptake inhibitors) use, and 2 other interventions for Depressive Disorder and Cancer. Completed, enrolled 50,430 participants.
Detailed Summary
There is a lack of toxicology data on one bupropion metabolite, and limited literature examining bupropion use and cancer risk. This study evaluates the association between bupropion exposure and the development of cancer of the prostate, breast, lung, colon/rectum, urinary bladder, and uterus by comparing the risk of cancer in bupropion users with other antidepressant users. Because there is no evidence that bupropion is associated with any particular cancer, we have chosen the six most common cancers diagnosed in the United States to optimize statistical power/precision for cancer-site specific comparisons. Two US population-based data resources with automated claims, pharmacy, and tumor registry data are included in this study. Using a nested case-control design, this study will compare the incidence of cancer in patients exposed to bupropion with the incidence in patients exposed to other antidepressants.
Study Details
Timeline
Interventions
Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An "other antidepressant" would be any antidepressant other than bupropion, a SSRI or a TCA.